Skip to Content

New Drug Approvals Archive - April 2014

See also: New Indications and Dosage Forms for April 2014

April 2014

Evzio (naloxone hydrochloride)

Date of Approval: April 3, 2014
Company: Kaleo Inc.
Treatment for: Opioid Overdose

Evzio (naloxone hydrochloride) is an opioid antagonist hand-held auto-injector indicated for the emergency treatment of known or suspected opioid overdose.

Tanzeum (albiglutide) Injection

Date of Approval: April 15, 2014
Company: GlaxoSmithKline (GSK) plc
Treatment for: Diabetes Type 2

Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.

Ragwitek (ragweed pollen allergen extract)

Date of Approval: April 17, 2014
Company: Merck & Co., Inc.
Treatment for: Ragweed Allergies

Ragwitek (short ragweed pollen allergen extract) is a sublingual immunotherapy for the treatment of ragweed allergies.

Xulane (ethinyl estradiol and norelgestromin) Transdermal System

Date of Approval: April 16, 2014
Company: Mylan Inc.
Treatment for: Contraception

Xulane (ethinyl estradiol and norelgestromin transermal system) is a generic version of Ortho Evra, a birth control patch used to prevent pregnancy.

Cyramza (ramucirumab) Injection

Date of Approval: April 21, 2014
Company: Eli Lilly and Company
Treatment for: Gastric Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Hepatocellular Carcinoma

Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:

  • as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
  • in combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
  • in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
  • as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.

Sylvant (siltuximab) for Injection

Date of Approval: April 22, 2014
Company: Janssen Research & Development, LLC
Treatment for: Multicentric Castleman's Disease

Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.

Zykadia (ceritinib) Capsules

Date of Approval: April 29, 2014
Company: Novartis Pharmaceuticals Corporation
Treatment for: Non-Small Cell Lung Cancer

Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Purixan (mercaptopurine) Oral Suspension

Date of Approval: April 28, 2014
Company: Nova Laboratories, Ltd.
Treatment for: Acute Lymphoblastic Leukemia

Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia.

Incruse Ellipta (umeclidinium) Inhalation Powder

Date of Approval: April 30, 2014
Company: GlaxoSmithKline
Treatment for: Chronic Obstructive Pulmonary Disease -- Maintenance

Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.